Adrafinil-induced orofacial dyskinesia.
We describe the first case of orofacial abnormal movements induced by adrafinil, a vigilance promoting agent of the same pharmacological class as modafinil. The dyskinesias did not spontaneously recover despite adrafinil withdrawal for a 4-month period. They were secondly dramatically improved by tetrabenazine, a presynaptic dopaminergic depleting drug which was introduced after the 4-month adrafinil-free period.
Department of Neurology, The Pierre Wertheimer Neurological Hospital, Lyon, France. stephane.thobois@chu-lyon.fr
Stéphane
S
Thobois
Jing
J
Xie
Helena
H
Mollion
Isabelle
I
Benatru
Emmanuel
E
Broussolle
D000368:Aged; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D006877:Hydroxamic Acids / Q000009:adverse effects*; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D013747:Tetrabenazine / Q000627:therapeutic use
D018726:Anti-Dyskinesia Agents; D000959:Antihypertensive Agents; D006877:Hydroxamic Acids; C022116:adrafinil; D013747:Tetrabenazine